期刊
IMMUNITY
卷 45, 期 4, 页码 917-930出版社
CELL PRESS
DOI: 10.1016/j.immuni.2016.09.015
关键词
-
类别
资金
- Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) [APP1108533]
- CFAR Developmental Award (NIH/NIAID) [5P30AI060354]
- HHMI International Student Research Fellowship
- Research Scholar Career Award of the Quebec Health Research Fund
- NIAID [AI104715]
- NSF Graduate Research Fellowship
- Ragon Institute
- Searle Scholars Program
- Beckman Young Investigator Program
- NIH New Innovator Award [DP2 OD020839]
- NIH from NIAID [U24 AI11862-01]
CD8(+) T cell recognition of virus-infected cells is characteristically restricted by major histocompatibility complex (MHC) class I, although rare examples of MHC class II restriction have been reported in Cd4-deficient mice and a macaque SIV vaccine trial using a recombinant cytomegalovirus vector. Here, we demonstrate the presence of human leukocyte antigen (HLA) class II-restricted CD8(+) T cell responses with antiviral properties in a small subset of HIV-infected individuals. In these individuals, T cell receptor beta (TCR beta) analysis revealed that class II-restricted CD8(+) T cells underwent clonal expansion and mediated killing of HIV-infected cells. In one case, these cells comprised 12% of circulating CD8(+) T cells, and TCR alpha analysis revealed two distinct co-expressed TCRa chains, with only one contributing to binding of the class II HLA-peptide complex. These data indicate that class II-restricted CD8(+) T cell responses can exist in a chronic human viral infection, and may contribute to immune control.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据